Reversing cachexia

Research output: Contribution to journalArticle

View graph of relations Save citation

Open

Authors

  • Michael J. Tisdale

Research units

Abstract

Muscle atrophy (cachexia) in cancer patients is a life-threatening condition for which therapeutic options are limited. Zhou et al. (2010) now identify a new target for treating cachexia, the activin type-2 receptor (ActRIIB). In several mouse models of cachexia, the authors reversed wasting of skeletal and cardiac muscle and increased life span by blocking ActRIIB with a decoy receptor.

Details

Original languageEnglish
Pages (from-to)511-512
Number of pages2
JournalCell
Volume142
Issue number4
DOIs
Publication statusPublished - 20 Aug 2010

Employable Graduates; Exploitable Research

Copy the text from this field...